buy management discuss earli qinlock
treatment gastrointestin stromal tumor gist patient previous receiv
least kinas inhibitor includ gleevec nv discuss management
highlight readi launch week given anticip recent earli
approv target agent see earli approv note retevmo tabrecta
novn-swx tukysa ayvakit qinlock launch
month wac price mgmt-estim free drug suppli gross-to-
net adjust commercially-insur patient updat estim account
launch maintain buy pt
qinlock ripretinib approv fda month ahead pdufa date
gist management prepar launch week given anticip potenti
earli approv fda label gist patient previous receiv least
prior kinas inhibitor one imatinib gleeven nv recal approv
base result success phase invictu trial read best-in-class result
kit-driven gist see invictu success note line bullish view see
placebo despit mo formal test secondari endpoint henc posit
management highlight echocardiogram recommend rather requir
fda label think ripretinib toxic profil nevertheless clean
late-lin patient popul analyst question post-approv
call center around cardiac dysfunct potenti need echocardiogram prior
treatment initi management discuss highlight scan recommend
per clinician judgment rather explicit requir overal qinlock safeti profil
look favor given black box warn vs standard-of-car gist therapi
sutent stivarga bayri black box low discontinu rate
vs placebo
assum net price line wac price
estim free drug estim gross-to-net adjust management highlight
call qinlock wac price reflect best-in-class profil
estim free drug support patient assist program pap line
oral oncolog agent caveat includ potenti free drug discount wac price
fluctuat quarter-to-quart basi well potenti higher util
patient assist program given impact us employ henc health
insur coverag current forecast net qinlock sale
conserv assum market penetr respect estim
total address market qinlock us line
line kit gist base treat patient estim
line line respect
earli clinical-stag pipelin opportun shift focu ahead phase
intrigu readout inhibitor updat phase data
tenosynovi giant cell tumor tgct patient around time plan
select initi potenti expans cohort inhibitor rebastinib
read updat data highlight abstract text promis initi
efficaci paclitaxel pass simon threshold need proceed
studi see abstract takeaway phase data carboplatin schedul
expect submit ind autophagi ulk inhibitor
phase intrigu remain track complet enrol
potenti readout trial enrol increas patient
page analyst certif import disclosur
see earn note statist plan unchang remain confid
success given invictu month mpf hazard ratio hr gist
exce sutent gist month hr furthermor compani
expect read addit qinlock phase cohort includ potenti
initi look smolder advanc system mastocytosi
updat model estim account earli approv month pdufa date
maintain buy pt
valuat price target per share base probability-adjust estim
gist net cash balanc sheet year use
discount cash flow analysi use wacc termin growth
rate appli termin year post-assum gener entri
risk risk rate valuat includ regulatori
commerci setback potenti emerg new competitor lower product
sale expect cash flow neg compani may also engag financ
activ dilut exist sharehold
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
